242 results on '"Jhund, P. S."'
Search Results
2. Author Correction: Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial
3. Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial
4. Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER
5. Generalizability of the Spectrum of Kidney Risk in the FINEARTS-HF Trial to U.S. Adults With Heart Failure.
6. The Global Ambulatory Blood Pressure Monitoring (ABPM) in Heart Failure with Preserved Ejection Fraction (HFpEF) Registry. Rationale, design and objectives
7. Development and external validation of prognostic models to predict sudden and pump-failure death in patients with HFrEF from PARADIGM-HF and ATMOSPHERE
8. Developing and validating models to predict sudden death and pump failure death in patients with heart failure and preserved ejection fraction
9. Dapagliflozin and Timing of Prior Heart Failure Hospitalization
10. Low Natriuretic Peptide Levels and Outcomes in Patients With Heart Failure and Preserved Ejection Fraction
11. Incidence of cardiovascular diseases over the past 20 years - a population-based study in 22 million individuals
12. Relationship between change in Kansas City Cardiomyopathy Questionnaire scores and outcomes in patients with HFrEF
13. Effect of eplerenone according to duration of heart failure in EMPHASIS-HF: It is never too late to start an MRA in HFrEF
14. Effect of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction treated with beta-blockers: the DELIVER trial
15. Effects of dapagliflozin in heart failure with preserved ejection fraction and chronic obstructive pulmonary disease: an analysis of the DELIVER trial
16. Effect of dapagliflozin on outpatient worsening heart failure in patients with mildly reduced or preserved ejection fraction: the DELIVER trial
17. Effect of empagliflozin on CMR-estimated pulmonary capillary wedge pressure in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF)
18. Effect of dapagliflozin in patients in Asia with heart failure with mildly reduced or preserved ejection fraction: insights from DELIVER
19. Association of CA-125 with markers of congestion, and effect of empagliflozin on CA-125 in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF)
20. Covariate adjusted reanalysis of the I-Preserve trial
21. Glomerular filtration rate by differing measures, albuminuria and prediction of cardiovascular disease, mortality and end-stage kidney disease
22. Sex Differences in Heart Failure With Improved Ejection Fraction
23. Prognostic Models for Mortality and Morbidity in Heart Failure With Preserved Ejection Fraction
24. Heart Failure, Investigator-Reported Sleep Apnea and Dapagliflozin: A Patient-Level Pooled Meta-Analysis of DAPA-HF and DELIVER.
25. Efficacy of an implantable cardioverter-defibrillator in patients with diabetes and heart failure and reduced ejection fraction
26. “Real World” Eligibility for Sacubitril/Valsartan in Unselected Heart Failure Patients: Data from the Swedish Heart Failure Registry
27. Contemporary Management of Heart Failure in the Elderly
28. Dapagliflozin and Mode of Death in Heart Failure With Improved Ejection Fraction: A Post Hoc Analysis of the DELIVER Trial
29. A novel, small-volume subcutaneous furosemide formulation delivered by an abdominal patch infusor device in patients with heart failure: results of two phase I studies
30. Effects of renin–angiotensin system blockers on outcomes from COVID-19: a systematic review and meta-analysis of randomized controlled trials
31. Efficacy of Dapagliflozin According to Heart Rate: A Patient-Level Pooled Analysis of DAPA-HF and DELIVER.
32. Duration of Heart Failure With Preserved Ejection Fraction and Outcomes With Sacubitril/Valsartan: Insights From the PARAGON-HF Trial.
33. Dapagliflozin and Apparent Treatment-Resistant Hypertension in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The DELIVER Trial
34. Dapagliflozin and Physical and Social Activity Limitations in Heart Failure With Reduced Ejection Fraction
35. Operational challenges and mitigation measures during the COVID-19 pandemic–Lessons from DELIVER.
36. Predicting Stroke in Heart Failure and Preserved Ejection Fraction Without Atrial Fibrillation.
37. Outcomes related to IGFBP-7 in patients with heart failure and reduced ejection fraction and effects of dapagliflozin: findings from DAPA-HF
38. History of stroke in patients with heart failure: prevalence, baseline characteristics and clinical outcomes
39. Long-term cardiovascular outcomes in five-year cancer survivors: a nationwide cohort study
40. Efficacy and safety of sacubitril/valsartan according to frailty in heart failure with preserved ejection fraction: a post hoc analysis of the PARAGON-HF trial
41. Prevalent and incident anaemia in PARADIGM-HF and effect of sacubitril/valsartan
42. Relationship between endothelin-1, heart failure with reduced ejection fraction and dapagliflozin: findings from DAPA-HF
43. Stroke in patients with heart failure and reduced ejection fraction without atrial fibrillation: external validation of a risk model
44. Alkaline phosphatase and bilirubin combined are a powerful predictor of outcome in patients with heart failure and reduced ejection fraction: an analysis of the ATMOSPHERE and PARADIGM-HF trials
45. A comprehensive study of the incremental prognostic value of novel biomarkers in PARADIGM-HF (Bio-PREDICT-HF)
46. Implications of the 2021 CKD-EPI cystatin C/creatinine eGFR equation for eligibility for therapy in HFrEF: insights from PARADIGM-HF
47. Prevalence of Prediabetes and Undiagnosed Diabetes in Patients with HFpEF and HFrEF and Associated Clinical Outcomes
48. Author Correction: Glomerular filtration rate by differing measures, albuminuria and prediction of cardiovascular disease, mortality and end-stage kidney disease
49. Clinical Characteristics and Outcomes in Patients With Heart Failure: Are There Thresholds and Inflection Points in Left Ventricular Ejection Fraction and Thresholds Justifying a Clinical Classification?
50. Association of Dapagliflozin vs Placebo With Individual Kansas City Cardiomyopathy Questionnaire Components in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the DELIVER Trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.